##common.pageHeaderLogo.altText##
DOI:
https://doi.org/10.57187/5110

Clinical reasoning: Case report

Vol. 156 No. 7 (2026)

Nocardia farcinica septic bursitis – a case report and scoping literature review

Cite this as:
Swiss Med Wkly. 2026;156:5110
Published
08.07.2026

Summary

BACKGROUND: Septic bursitis is mainly caused by Staphylococcus aureus and Streptococcus spp. However, patients with immunosuppression may develop infections caused by rare pathogens. Here, we describe a case of septic olecranon bursitis caused by Nocardia farcinica and provide a literature review of musculoskeletal infections caused by this pathogen.

CASE PRESENTATION:  A male patient in his mid-70s with seronegative rheumatoid arthritis who was receiving methotrexate, low-dose prednisone, and golimumab experienced trauma to the elbow, followed by progressive painful swelling, slight erythema, and the formation of a fistula draining cloudy fluid over the subsequent two weeks. Culture of the aspirated bursal fluid yielded slow-growing yellow-pigmented colonies identified as Nocardia farcinica. Whole-genome sequencing confirmed the species without detecting any known virulence genes or resistance mutations. Clinical and radiological evaluation showed no signs of systemic dissemination. The patient underwent surgical bursectomy and received targeted antimicrobial therapy with oral trimethoprim/sulfamethoxazole. After 3 weeks, the patient developed a systemic allergic reaction, necessitating a switch to susceptibility-guided amoxicillin/clavulanate. Treatment was continued for 3 months, ultimately resulting in the complete and successful resolution of the bursitis.

CONCLUSION: This report highlights that it is important for clinicians to consider rare pathogens in immunosuppressed patients with bursitis, especially in those presenting with atypical courses. Localised musculoskeletal infections caused by Nocardia are mostly treated with a combined surgical and antibiotic approach. Antibiotics are typically administered for one to six months. In cases of surgical removal, a shorter antibiotic treatment duration seems sufficient. A multidisciplinary approach involving infectious diseases specialists, microbiologists, and surgeons is critical for achieving favourable outcomes.

References

  1. 1. McAfee J, Smith D. Olecranon and prepatellar bursitis. Diagnosis and treatment. Western Journal of Medicine. 1988;149(5) doi: 607.
  2. 2. Baumbach SF, Lobo CM, Badyine I, Mutschler W, Kanz KG. Prepatellar and olecranon bursitis: literature review and development of a treatment algorithm. Arch Orthop Trauma Surg. 2014 Mar;134(3):359–70. 10.1007/s00402-013-1882-7.359-70 doi: https://doi.org/10.1007/s00402-013-1882-7
  3. 3. Reilly D, Kamineni S. Olecranon bursitis. J Shoulder Elbow Surg. 2016 Jan;25(1):158–67. 10.1016/j.jse.2015.08.032.158-67 doi: https://doi.org/10.1016/j.jse.2015.08.032
  4. 4. Dutertre M, Delobel P, Marchou B, Boyer JF, Mougari F, Martin-Blondel G. Olecranon bursitis secondary to Mycobacterium europaeum infection in a patient receiving immunosuppressive drugs for rheumatoid arthritis. Med Mal Infect. 2019 Aug;49(5):358–9. 10.1016/j.medmal.2019.03.002.358-9 doi: https://doi.org/10.1016/j.medmal.2019.03.002
  5. 5. Traxler RM, Bell ME, Lasker B, Headd B, Shieh WJ, McQuiston JR. Updated review on Nocardia species: 2006–2021. Clin Microbiol Rev. 2022 Dec;35(4):e0002721. 10.1128/cmr.00027-21.e00027-21 doi: https://doi.org/10.1128/cmr.00027-21
  6. 6. Sayegh ET, Strauch RJ. Treatment of olecranon bursitis: a systematic review. Arch Orthop Trauma Surg. 2014 Nov;134(11):1517–36. 10.1007/s00402-014-2088-3.1517-36 doi: https://doi.org/10.1007/s00402-014-2088-3
  7. 7. Fatahi-Bafghi M. Nocardiosis from 1888 to 2017. Microb Pathog. 2018 Jan;114:369–84. 10.1016/j.micpath.2017.11.012.369-84 doi: https://doi.org/10.1016/j.micpath.2017.11.012
  8. 8. Wilson JW, editor. Nocardiosis: updates and clinical overview. Mayo Clinic Proceedings. Elsevier; 2012.
  9. 9. Nocard E. Note sur la maladie des boeufs de Guadeloupe connue sous le nom de farcin. Ann Inst Pasteur (Paris). 1888;2: 293-302.
  10. 10. Beaman BL, Beaman L. Nocardia species: host-parasite relationships. Clin Microbiol Rev. 1994 Apr;7(2):213–64. 10.1128/CMR.7.2.213.213-64 doi: https://doi.org/10.1128/CMR.7.2.213
  11. 11. Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ Jr. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev. 2006 Apr;19(2):259–82. 10.1128/CMR.19.2.259-282.2006.259-82 doi: https://doi.org/10.1128/CMR.19.2.259-282.2006
  12. 12. Steinbrink J, Leavens J, Kauffman CA, Miceli MH. Manifestations and outcomes of nocardia infections: comparison of immunocompromised and nonimmunocompromised adult patients. Medicine (Baltimore). 2018 Oct;97(40):e12436. 10.1097/MD.0000000000012436.e12436 doi: https://doi.org/10.1097/MD.0000000000012436
  13. 13. Toyokawa M, Ohana N, Ueda A, Imai M, Tanno D, Honda M, et al. Identification and antimicrobial susceptibility profiles of Nocardia species clinically isolated in Japan. Sci Rep. 2021 Aug;11(1):16742. 10.1038/s41598-021-95870-2.16742 doi: https://doi.org/10.1038/s41598-021-95870-2
  14. 14. Wang H, Zhu Y, Cui Q, Wu W, Li G, Chen D, et al. Epidemiology and Antimicrobial Resistance Profiles of the Nocardia Species in China, 2009 to 2021. Microbiol Spectr. 2022 Apr;10(2):e0156021. 10.1128/spectrum.01560-21.e0156021 doi: https://doi.org/10.1128/spectrum.01560-21
  15. 15. Nathar S, Rajmichael R, Jeyaraj Pandian C, Nagarajan H, Mathimaran A, Kingsley JD, et al. Exploring Nocardia’s ecological spectrum and novel therapeutic frontiers through whole-genome sequencing: unraveling drug resistance and virulence factors. Arch Microbiol. 2024 Jan;206(2):76. 10.1007/s00203-023-03799-z.76 doi: https://doi.org/10.1007/s00203-023-03799-z
  16. 16. Liu Y, Wu SY, Deng J, Zhuang KW, Tang Y, Wu N, et al. Application of MALDI-TOF mass spectrometry for identification of Nocardia species. BMC Microbiol. 2024 Sep;24(1):358. 10.1186/s12866-024-03483-2.358 doi: https://doi.org/10.1186/s12866-024-03483-2
  17. 17. Schlaberg R, Chiu CY, Miller S, Procop GW, Weinstock G; Professional Practice Committee and Committee on Laboratory Practices of the American Society for Microbiology; Microbiology Resource Committee of the College of American Pathologists. Validation of Metagenomic Next-Generation Sequencing Tests for Universal Pathogen Detection. Arch Pathol Lab Med. 2017 Jun;141(6):776–86. 10.5858/arpa.2016-0539-RA.776-86 doi: https://doi.org/10.5858/arpa.2016-0539-RA

Most read articles by the same author(s)